SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
Status:
Not yet recruiting
Trial end date:
2026-10-02
Target enrollment:
Participant gender:
Summary
The goal of this randomized, double-blinded, controlled clinical trial is to investigate if
treatment with an sodium-glucose cotransporter-2 inhibitor (SGLT2) during the unique time
window before coronary artery bypass surgery (CABG), can reduce the incidence of
post-operative atrial fibrillation and/or acute kidney injury in patients with chronic
coronary syndrome. The main questions it aims to answer are:
- Does treatment with an SGLT2 inhibitor during the waiting time and stable post-operative
period, in patients with chronic coronary syndrome scheduled for CABG, reduce the risk
of new onset atrial fibrillation compared to placebo?
- Does treatment with an SGLT2 inhibitor during the waiting time and stable post-operative
period, in patients with chronic coronary syndrome scheduled for CABG, reduce the risk
of acute kidney injury before hospital discharge compared to placebo? Participants will
be administered dapagliflozin 10 mg once daily or placebo for a minimum of seven days
while awaiting scheduled CABG and up until discharge, with a short interruption for
surgery. Researchers will compare the active arm to the placebo arm to see if
dapagliflozin can reduce the incidence of post-operative atrial fibrillation and/or
acute kidney injury in patients with chronic coronary syndrome.
Phase:
Phase 4
Details
Lead Sponsor:
Region Örebro County
Collaborators:
Aarhus University Hospital Brigham and Women's Hospital Göteborg University Harvard Medical School (HMS and HSDM) London School of Hygiene and Tropical Medicine Odense University Hospital Örebro University, Sweden Sahlgrenska University Hospital, Sweden Skane University Hospital Swedish Heart Lung Foundation The Swedish Research Council University of Leeds